Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of $78.00. The company’s shares opened today at $47.95.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback